Although erlotinib exposure was similar in patients with moderately impaired hepatic function (Child-Pugh score 7-9) compared with patients with adequate hepatic function, caution should be used when administering Tarceva to patients with hepatic impairment.
Varovaisuutta on kuitenkin syytä noudattaa, jos Tarcevaa annetaan maksan vajaatoimintaa sairastaville potilaille.